natgillin/translations-raw huggingface dataset:
CYP3A4-metabolised and/or P-gp substrates known to prolong the QT interval may be contraindicated with Ketoconazole HRA, since the combination may lead to an increased risk of ventricular tachyarrhythmias, including occurrences of torsade de pointes, a potentially fatal arrhythmia (see section 4.3).
Primjena supstrata koji se metaboliziraju posredstvom CYP3A4 i/ili supstrata P-glikoproteina, koji produljuju QT interval može biti kontraindicirana s Ketoconazoleom HRA, budući da njihova primjena u kombinaciji može uzrokovati povećan rizik od ventrikularne tahiaritmije, uključujući pojavu torsade de pointes, potencijalno fatalne aritmije (vidjeti dio 4.3).
CYP3A4/5 inhibitors have been shown to have a significant effect on the pharmacokinetics of guanfacine when co-administered.
Pokazalo se da inhibitori CYP3A4/5 imaju značajan učinak na farmakokinetiku gvanfacina kad se primjenjuju istovremeno.
CYP3A4/5 substrates including immunosuppressants
Supstrati CYP CYP3A4/5 uključujući imunosupresive
CYP450 inducer]
induktor CYP450]
Cyprus/ Κύπρος
Cipar/Κύπρος
Cyramza 10 mg/ml concentrate for solution for infusion
Cyramza 10 mg/ml koncentrat za otopinu za infuziju
Cyramza 10 mg/ml sterile concentrate ramucirumab
Cyramza 10 mg/ml sterilni koncentrat ramucirumab
Cyramza as a single agent
Cyramza u monoterapiji
Cyramza at 10 mg/kg or placebo and docetaxel at 75 mg/m2 were each administered by intravenous infusion on day 1 of a 21-day cycle.
Cyramza u dozi od 10 mg/kg ili placebo te docetaksel u dozi od 75 mg/m2 primjenjivali su se svaki intravenskom infuzijom 1. dana 21-dnevnog ciklusa.
Cyramza has been shown to increase survival of patients with advanced gastric or gastro-oesophageal junction cancer, metastatic colorectal cancer and advanced or metastatic non-small cell lung cancer whose disease has worsened despite treatment with other medicines in 4 main studies.
Utvrđeno je da lijek Cyramza povećava stopu preživljenja u bolesnika s naprednim stadijem gastričnog karcinoma ili s karcinomom gastroezofagealnog spoja, metastatskim kolorektalnim karcinomom i naprednim ili metastatskim rakom nemalih stanica pluća, kod kojih se bolest pogoršala unatoč terapiji drugim lijekovima u 4 glavna ispitivanja.
Cyramza has no known influence on the ability to drive and use machines.
Nema poznatih učinaka lijeka Cyramza na sposobnost upravljanja vozilima i rada sa strojevima.
Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
Cyramza je u kombinaciji s docetakselom indicirana za liječenje lokalno uznapredovalog ili metastatskog raka pluća nemalih stanica (engl. non-small cell lung cancer, NSCLC) u odraslih bolesnika kod kojih je došlo do progresije bolesti nakon prethodne kemoterapije utemeljene na platini.
Cyramza is a cancer medicine used to treat adult patients with:
Lijek Cyramza je citostatik koji se koristi za liječenje odraslih bolesnika sa sljedećim bolestima:
Cyramza is available as a concentrate to be made up into a solution for infusion (drip) into a vein.
Lijek Cyramza dostupan je kao koncentrat za pripravak otopine za infuziju (drip) u venu.
Cyramza is available in packs of:
Cyramza je dostupna u pakiranjima od:
Cyramza is used in combination with another medicine, paclitaxel, or on its own if the combination with paclitaxel is not appropriate, in patients whose disease has worsened despite treatment with medicines containing platinum or fluoropyrimidines; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Lijek Cyramza koristi se u kombinaciji s drugim lijekom, paklitakselom, ili kao monoterapija ako kombinacija s paklitakselom nije primjerena, u bolesnika kod kojih je zabilježeno pogoršanje bolesti unatoč terapiji lijekovima koji sadrže platinu ili fluoropirimidin; metastazirani kolorektalni karcinom (rak debelog crijeva koji se proširio na ostale dijelove tijela).
Cyramza is used in combination with docetaxel in patients whose disease has worsened despite treatment with medicines containing platinum.
Lijek Cyramza koristi se u kombinaciji s docetakselom u bolesnika čija se bolest pogoršala unatoč terapiji lijekovima koji sadrže platinu.
Cyramza is used with ‘FOLFIRI’ chemotherapy (a combination of fluorouracil, folinic acid and irinotecan) in patients whose disease has worsened despite treatment with bevacizumab, oxaliplatin and a fluoropyrimidine; non-small cell lung cancer that is advanced or has spread to other parts of the body.
Lijek Cyramza koristi se zajedno s kemoterapijom „FOLFIRI” (kombinacija fluorouracila, folne kiseline i irinotekana) u bolesnika čija se bolest pogoršala unatoč liječenju bevacizumabom, oksaliplatinom i fluoropirimidinom; rak nemalih stanica pluća koji je u naprednom stadiju ili se proširio na ostale dijelove tijela.
Cyramza plus docetaxel (N=627)
Cyramza plus docetaksel (N=627)
Cyramza plus docetaxel N=628
Cyramza plus docetaksel N=628
Cyramza plus paclitaxel (N=327)
Cyramza plus paklitaksel (N=327)
Cyramza plus paclitaxel N=330
Cyramza plus paklitaksel N=330
Cyramza treatment will be permanently stopped if you:
Liječenje lijekom Cyramza trajno će se obustaviti ako:
Cyramza treatment will be temporarily stopped if you:
Liječenje lijekom Cyramza privremeno će se prekinuti ako:
Cyramza was also shown to prolong survival of patients with colorectal and non-small cell lung cancer.
Također je utvrđeno da je lijek Cyramza omogućio dulje preživljenje bolesnika s kolorektalnim karcinomom i rakom nemalih stanica pluća.
Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
Cyramza je, u kombinaciji s protokolom FOLFIRI (irinotekan, folatna kiselina i 5-fluorouracil), indicirana za liječenje metastatskog kolorektalnog raka u odraslih bolesnika kod kojih je došlo do progresije bolesti tijekom ili nakon prethodne terapije bevacizumabom, oksaliplatinom i fluoropirimidinom.
Cyst formation in your pancreas
tvaranje ciste u gušterači
Cyst in the kidney
cista u bubregu
cyst, facial pain, localised oedema
amenoreja, vaginalno krvarenje
Cystadane is a white crystalline free flowing powder.
Cystadane je bijeli kristalinični sipki prašak.
Cystagon 150 mg: white, opaque hard capsules with CYSTAGON 150 on the body and MYLAN on the cap.
Cystagon 150 mg: bijele, neprozirne tvrde kapsule s CYSTAGON 150 na tijelu i MYLAN na kapici.
Cystagon 50 mg: white, opaque hard capsules with CYSTA 50 on the body and MYLAN on the cap.
Cystagon 50 mg: bijele, neprozirne tvrde kapsule s CYSTA 50 na tijelu i MYLAN na kapici.
CYSTAGON has minor or moderate influence on the ability to drive and use machines
CYSTAGON malo ili umjereno utječe na sposobnost upravljanja vozilima i rada na strojevima.
CYSTAGON has minor or moderate influence on the ability to drive ans use machines
CYSTAGON malo ili umjereno utječe na sposobnost upravljanja vozilima i rada na strojevima.
CYSTAGON has not been shown to prevent cystine crystals accumulating in the eye.
Nije se pokazalo da CYSTAGON sprečava nakupljanje kristala cistina u oku.
CYSTAGON may cause drowsiness.
CYSTAGON može dovesti do pospanosti.
CYSTAGON must not be used during breast-feeding.
CYSTAGON se ne smije koristiti tijekom dojenja.
CYSTAGON should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.6 and section 5.3 as it is teratogenic in animals.
CYSTAGON se ne smije koristiti tijekom trudnoće, osobito tijekom prvog tromjesečja, osim ako nije izričito neophodan (vidjeti dio 4.6 te dio 5.3) jer je teratogen kod životinja.
CYSTAGON treatment should be initiated under the supervision of a physician experienced in the treatment of cystinosis.
Liječenje lijekom CYSTAGON treba započeti pod nadzorom liječnika s iskustvom u liječenju cistinoze.
Cysteamine (mercaptamine bitartrate)
cisteamin (merkaptaminditartarat)
Cysteamine bitartrate (CYSTAGON) is bioequivalent to cysteamine hydrochloride and phosphocysteamine.
Cisteaminditartrat (CYSTAGON) bioekvivalentan je cisteamin hidrokloridu i fosfocisteaminu.
Cysteamine bitartrate is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in vitro.
Cisteamin bitartrat in vitro nije inhibitor enzima CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 i CYP3A4.
Cysteamine bitartrate is not an inhibitor of OAT1, OAT3 and OCT2.
Cisteamin bitartrat nije inhibitor OAT1, OAT3 i OCT2.
Cysteamine bitartrate should not be administered with food rich in fat or proteins, or with frozen food like ice-cream.
Cisteamin bitartrat se ne smije primjenjivati uz hranu bogatu mastima ili proteinima ili uz smrznutu hranu kao što je sladoled.
Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function studies.
Cisteamin se ponekad povezuje s reverzibilnom leukopenijom i abnormalnim rezultatima jetrenih funkcija.
Cysteamine is the simplest stable aminothiol and a degradation product of the amino acid cysteine.
Cisteamin je najjednostavniji stabilni aminotiol i proizvod degradacije aminokiselinecisteina.
Cysteamine may cause drowsiness.
Cisteamin može uzrokovati pospanost.
Cysteamine participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.
Cisteamin sudjeluje unutar lizosoma u reakciji razmjene tiodisulfida pretvarajući cistin u cistein i cistein-cisteamin miješani disulfid, od kojih oba mogu napustiti lizosom kod bolesnika s cistinozom.
Cysteamine reacts with cystine to form the mixed disulfide of cysteamine and cysteine.
Cisteamin reagira s cistinom stvarajući miješani disulfid cisteamina i cisteina, te cistein.
Cysteamine therapy must be initiated promptly once the diagnosis is confirmed (i.e., increased WBC cystine) to achieve maximum benefit.
Liječenje cisteaminom mora se započeti odmah nakon potvrde dijagnoze (tj. povišenog cistina u leukocitima) kako bi se postigao maksimalni povoljni učinak.
Cysteamine therapy should be initiated promptly after confirmation of the diagnosis of cystinosis to achieve maximum benefit.
Liječenje cisteaminom mora se započeti odmah nakon potvrde dijagnoze kako bi se postigao najveći povoljni učinak.
Cystic fibrosis is an inherited disease that mainly affects the cells that secrete mucus in the lungs, and the cells that secrete digestive juices from the glands in the gut and pancreas.
Cistična fibroza je nasljedna bolest koja uglavnom zahvaća stanice koje luče sekret u plućima te stanice koje luče probavne tekućine iz žlijezdi u crijevima i gušterači.
Cystic fibrosis is caused by mutations in the CFTR gene.
Cističnu fibrozu uzrokuje mutacija u genu CFTR.
Cystic fibrosis is caused by mutations of the CFTR gene.
Cističnu fibrozu uzrokuju mutacije gena CFTR.
Cystine levels in white blood cells (which are measured as nmol hemicystine per mg white blood cell protein), or alternatively mercaptamine concentration in the blood, should be monitored and used to adjust the dose, which should never exceed 1.95 g per m2 per day.
Umnažanje je dopušteno samo uz citiranje izvora. alternativno koncentraciju merkaptamina u krvi treba nadzirati i koristiti kao bi se prilagodila koja nikad ne bi smjela premašiti 1,95 g po m2 na dan.
Cystinosis is a disease affecting how the body functions, with an abnormal accumulation of the amino acid cystine in various organs of the body such as the kidney, eye, muscle, pancreas, and brain.
Cistinoza je bolest koja zahvaća način na koji tijelo radi, s abnormalnim nakupljanjem aminokiseline cistina u različitim organima u tijelu kao to su bubrezi, oči, mišići, gušterača i mozak.
Cystinosis is a metabolic disease called ‘nephropathic cystinosis’ which is characterized by an abnormal accumulation of the amino acid cystine in various organs of the body such as the kidney, eye, muscle, pancreas, and brain.
Cistinoza je metabolička bolest zvana 'nefropatska cistinoza' koju karakterizira abnormalno nakupljanje aminokiseline cistina u raznim tjelesnim organima poput bubrega, oka, mišića, gušterače i mozga.
Cystitis
cistitis
Cystitis
cistitis,
Cystitis haemorrhagic
Hemoragijski cistitis
Cystitis, vaginitis, oral candidiasis
cistitis, vaginitis, oralna kandidijaza
Cystoid macular oedema (CMO) has been reported in patients treated with docetaxel.
U bolesnika koji su liječeni docetakselom prijavljen je cistoidni edem makule (CMO).
Cystoid macular oedema (CMO) has been reported in patients treated with docetaxel.
U bolesnika liječenih docetakselom prijavljen je cistični edem makule (CEM).
Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
Cistoidni makularni edem (oticanje mrežnice u oku što dovodi do pogoršanja vida)
Cystoid Macular Oedema is considered to be a more severe subtype of macular oedema and currently only ‘macular oedema’ listed in the SmPC.
Cistoidni makularni edem smatra se ozbiljnijom podvrstom makularnog edema i trenutno je samo „makularni edem“ naveden u Sažetku opisa svojstava lijeka.
cystoid macular oedema, eye swelling, vision blurred
cistoidni makularni edem, oticanje oka, zamućen vid
cystoid macular oedema, vision blurred
cistoidni makularni edem, zamućen vid
Cysts in the lining of joints (synovial cysts)
ciste na ovojnici zglobova (sinovijalne ciste)
Cytarabine was clastogenic to meiotic cells; a dose-dependent increase in sperm-head abnormalities and chromosomal aberrations occurred in mice given intraperitoneal (i.p.) cytarabine.
Citarabin je djelovao klastogeno na stanice u mejozi; u miševa kod kojih je citarabin dan intraperitonealno (i.p.) nastupili su porast abnormalnosti glava spermatozoida i aberacije kromosoma ovisni o dozi.
Cytochrome (CYP) 450-mediated metabolic interactions are not anticipated as decitabine metabolism is not mediated by this system but by oxidative deamination.
Ne očekuju se metaboličke interakcije posredovane citokromom (CYP) 450 jer metabolizam decitabina nije posredovan tim sustavom nego putem oksidativne deaminacije.
Cytochrome P-450 2C9 substrates
Supstrati citokroma P 450 2C9
Cytochromes P450-
Citokromi P450-CYP1A2 i
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokromi P450-CYP1A2 i P450-CYP2D6 doprinose stvaranju N-desmetil i 2-hidroksimetil metabolita te u ispitivanjima na životinjama oba pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokromi P450-CYP1A2 i P450-CYP2D6 doprinose stvaranju N-dezmetil i 2-hidroksimetil metabolita te u ispitivanjima na životinjama oba pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites; both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokromi P450-CYP1A2 i P450-CYP2D6 doprinose stvaranju N-dezmetil i 2-hidroksimetil metabolita koji u ispitivanjima na životinjama pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
Cytogenetic abnormalities are known to occur in SAA patients.
U bolesnika s teškom aplastičnom anemijom mogu se pojaviti citogenetske abnormalnosti.
Cytogenetic abnormalities were evaluated in 117 of the total population of 176patients.
Citogenetske abnormalnosti su procijenjene u 117 od ukupne populacije od 176 bolesnika.
Cytogenetic category
Citogenetska kategorija
Cytogenetic confirmation of conversion to a normal genotype and Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) detection of PML/RAR conversion to normal are shown in the table below.
Citogenetska potvrda konverzije u normalni genotip i detekcija konverzije PML/RAR u normalnu reakcijom obrnute transkriptaze - lančane polimeraze (RT-PCR), prikazane su u tablici u nastavku.
Cytogenetic Response
Citogenetički odgovor
Cytogenetic response
Citogenetski odgovor
Cytogenetic Response (%)
Citogenetski odgovor (%)
Cytogenetic response criteria:
2 Kriteriji citogenetskog odgovora:
Cytogenetic response criteria: complete (0% Ph+ metaphases), partial (1–35%), minor (36–65%) or minimal (66–95%).
Kriteriji citogenetskog odgovora: potpun (0% Ph+ metafaza), djelomičan (1-35%), manji (36-65%) ili minimalan (66-95%).
Cytogenetic Response criteria: Major Cytogenetic response included Complete (0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridization [FISH]) or partial (1%-35%) cytogenetic responses.
Kriteriji citogenetskog odgovora: veliki citogenetski odgovor uključivao je potpune (0% Ph+ metafaza u koštanoj srži ili < 1% pozitivnih stanica u fluorescentnoj in situ hibridizaciji [FISH]) ili parcijalne (1%-35%) citogenetske odgovore.
Cytogenetic response within 12 months
Citogenetski odgovor unutar 12 mjeseci
Cytogenetic responsec (%)
Citogenetski odgovorc (%)
Cytogenetic responses were based on the percentage of Ph+ metaphases among >/= 20 metaphase cells in each bone marrow sample.
Citogenetski odgovori su bili temeljeni na postotku Ph+ metafaza među >/= 20 metafaznih stanica u svakom uzorku koštane srži.
Cytogenetics after TRISENOX therapy
Citogenetika nakon terapije TRISENOXOM
Cytokine release related symptoms with higher intensities
Simptomi vezani uz otpuštanje citokina jačeg intenziteta
Cytokine release syndrome
indrom otpuštanja citokina
Cytokine release syndrome
sindrom otpuštanja citokina
Cytokine release syndrome (CRS) which may be life-threatening or fatal (grade ≥ 4) has been reported in patients receiving BLINCYTO (see section 4.8).
U bolesnika u kojih se primjenjuje BLINCYTO prijavljen je sindrom otpuštanja citokina (CRS, od eng. cytokine release syndrome), koji može biti opasan po život ili imati smrtan ishod (stupanj ≥ 4) (vidjeti dio 4.8).
Cytokine release syndrome and infusion reactions
Sindrom otpuštanja citokina i reakcije povezane s infuzijom
Cytokine release syndrome*, hypersensitivity*.
Sindrom otpuštanja citokina*, hipersenzitivnost
Cytokine release syndrome*, rigors*, chills*, hyperhidrosis*, fatigue*
sindrom oslobađanja citokina*, tresavica*, zimica*, hiperhidroza*, umor
Cytokine release syndromea
Sindrom otpuštanja citokina a
Cytokine storm Hypersensitivity
Citokinska oluja Preosjetljivost
Cytokine-refractory metastatic renal cell carcinoma
Metastatski karcinom bubrežnih stanica refraktoran na citokine
Cytokines are proteins made by your body that co- ordinate communication between cells and help control cell activity.
Citokini su bjelančevine koje stvara Vaše tijelo koji usklađuju komunikaciju između stanica i pomažu u kontroli stanične aktivnosti.
Cytokines are proteins made by your body that co-ordinate communication between cells and help control cell activity.
Citokini su bjelančevine koje stvara Vaše tijelo koji usklađuju komunikaciju između stanica i pomažu u kontroli stanične aktivnosti.
cytolytic hepatitis, liver function test abnormal
citolitički hepatitis, poremećeni testovi jetrene funkcije
Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.
Preporučuje se profilaksa infekcije citomegalovirusom (CMV) tijekom 3 mjeseca nakon transplantacije, posebice u bolesnika s povećanim rizikom od CMV infekcije.
cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus†
infekcija citomegalovirusom, reaktivacija infekcija poput infekcije citomegalovirusom, virusom hepatitisa B
cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus†
infekcija citomegalovirusom, reaktivacija infekcije kao što je citomegalovirus, virus hepatitisa B
Cytopaenias including pancytopaenia have been infrequently reported with Simponi in clinical trials.
Citopenije, uključujući pancitopeniju, prijavljene su rijetko u kliničkim ispitivanjima lijeka Simponi.
cytopenia
trombocitopenija
Cytopenias
Citopenije
Cytopenias, including rare severe neutropenia and thrombocytopenia, have been observed in patients treated with Plegridy.
Citopenije, uključujući i rijetku tešku neutropeniju i trombocitopeniju, primijećene su u bolesnika liječenih Plegridyjem.
CYTOTOXIC
CITOTOKSIČNO
CYTOTOXIC
CITOTOKSIČNO.
cytotoxic
Citotoksičan lijek
Cytotoxic
Citotoksično
Cytotoxic
Citotoksično.
Cytotoxic actions of erythropoietin on bone marrow cells could not be detected.
Nije primijećen citotoksični učinak eritropoetina na stanice koštane srži.
Cytotoxic agents
Citotoksični lijekovi
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Citotoksični lijekovi Tiazidi, uključujući hidroklorotiazid, mogu smanjiti izlučivanje citotoksičnih lijekova (npr. ciklofosfamid, metotreksat) putem bubrega i potencirati njihove mijelosupresivne učinke.
Cytotoxic agents: Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Citostatički lijekovi: Tiazidi, uključujući hidroklorotiazid, mogu smanjiti izlučivanje citostatika (npr. ciklofosfamid, metotreksat) bubrezima i potencirati njihove mijelosupresivne učinke.
Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because in addition to cancer cells it also kills other fast growing cells such as neutrophils, leaving the patient at risk of infections.
Citotoksična kemoterapija (lijekovi koji uništavaju stanice koje se brzo umnožavaju) uobičajeno uzrokuje neutropeniju jer pored stanica karcinoma uništava i druge stanice koje se brzo umnožavaju kao što su neutrofili te čini bolesnika podložnim infekcijama.
cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide.
citotoksični lijekovi (koriste se za liječenje raka), kao što su metotreksat ili ciklofosfamid.
cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
citotoksičnim lijekovima (koriste se za liječenje raka), kao što su metotreksat ili ciklofosfamid;
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a key regulator of T-cell activity.
Antigen 4 citotoksičnih limfocita T (CTLA-4) ključni je regulator aktivnosti T stanica.
CYTOTOXIC, special handling instructions (see package leaflet).
CITOTOKSIČAN LIJEK, vidjeti posebne upute za rukovanje (u uputi o lijeku).
Cytotoxic, special handling instructions (see package leaflet).
Citotoksičan lijek, posebne upute za rukovanje (vidjeti Uputu o lijeku).
CYTOTOXIC.
CITOTOKSIČNO.
Cytotoxic.
Citotoksično
Cytotoxic.
Citotoksično.
Cytotoxic: Handle with caution.
Citotoksičan lijek: rukovati s oprezom.
Cytotoxic: handle with caution.
Citotoksično: rukovati s oprezom.
Cytotoxic: handle with caution.
Citotoksično: rukujte s oprezom.
Cytotoxicity and haematological monitoring
Citotoksičnost i praćenje hematoloških parametara
CYTOTOXICS
CITOTOKSICI
CZ-74770 Opava - Komárov Czech Republic
CZ-74770 Opava - Komárov Češka
Czech republic/ Česká republika Angelini Pharma Česká republika s.r.o.
Češka Republika/Česká republika Angelini Pharma Česká republika s.r.o.
Cτ  22% Rilpivirine 
Cτ  22% rilpivirin 
Cτ  8% Boceprevir  (historical controls)
Cτ  8% boceprevir  (kontrole iz prethodnih ispitivanja)
Cτ  30% (induction of UGT1A1 and CYP3A enzymes)
Cτ  30% (indukcija enzima UGT1A1 i CYP3A)
Cτ  49% (induction of UGT1A1 and CYP3A enzymes)
Cτ  49% (indukcija enzima UGT1A1 i CYP3A)
Cτ  76% (induction of UGT1A1 and CYP3A enzymes)
Cτ  76% (indukcija enzima UGT1A1 i CYP3A)
C  45% Daclatasvir 
C  45% daklatazvir 
D - 65205 Wiesbaden
D – 65205 Wiesbaden Njemačka
D - 65205 Wiesbaden Germany
D – 65205 Wiesbaden Njemačka